Physician profile
Peter Torcivia
NPI 1154931723
$12,780.95
in general payments reported to CMS, 2019-2025
35 companies · $3,433 in 2025
The $3,433 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $833 · 2022: $2,624 · 2023: $2,798 · 2024: $3,093 · 2025: $3,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,217 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,217.27 |
| Education | $106.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,188.74 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,562.16 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,380.46 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,124.23 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $1,002.33 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $750.48 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $736.18 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $481.84 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Corium, LLC | $415.71 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $379.70 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $337.04 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $313.57 | 2021-2025 | Trintellix |
| Tris Pharma INC | $277.83 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $265.42 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $201.26 | 2022-2025 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $187.23 | 2023-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $159.86 | 2021-2024 | Jornay Pm |
| Piramal Critical Care | $124.98 | 2022 | |
| Sunovion Pharmaceuticals INC. | $121.20 | 2022 | |
| Idorsia Pharmaceuticals US INC | $99.69 | 2023-2025 | Quviviq, Quviviq |
| Eisai INC. | $86.24 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $85.84 | 2021-2022 | |
| Neos Therapeutics, Lp | $79.52 | 2021-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Vertical Pharmaceuticals, LLC | $71.20 | 2024-2025 | Relexxii |
| Almatica Pharma LLC | $50.41 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Arbor Pharmaceuticals, INC. | $46.31 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $46.08 | 2023 | Nuplazid |
| Azurity Pharmaceuticals, INC. | $45.78 | 2023-2025 | Horizant, Horizant |
| Jazz Pharmaceuticals INC. | $32.33 | 2021-2022 | |
| Livanova USA, INC. | $31.34 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Avion Pharmaceuticals | $21.11 | 2023 | Methylphenidate Hydrochloride |
| Biogen, INC. | $20.02 | 2024 | |
| Sage Therapeutics, LLC | $19.72 | 2023 | |
| Collegium Pharmaceutical, INC. | $19.58 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $15.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Torcivia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.